Evidence map›Paper›PMID 40178939›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025

Reproducibility of Plasma Metabolome over 1 Year in a Population-Based Cohort of Black Breast Cancer Survivors.

Bo Qin, Madhir Vyas, Steven C Moore, Xiaoyang Su, Eileen P White, Coral Omene, Tengteng Wang, Mi-Hyeon Jang, Kitaw Demissie, Chi-Chen Hong and 1 more

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bo QinCancer Prevention and Control Program, Rutgers Cancer Institute, New Brunswick, New Jersey.ORCID 0000-0003-2110-6050
Madhir VyasRutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.ORCID 0009-0001-2566-7296
Steven C MooreDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.ORCID 0000-0002-8169-1661
Xiaoyang SuRutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.ORCID 0000-0001-8081-1396
Eileen P WhiteCancer Metabolism and Immunology Program, Rutgers Cancer Institute, New Brunswick, New Jersey.ORCID 0000-0003-2961-3065
Coral OmeneRutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.ORCID 0000-0001-7824-1478
Tengteng WangCancer Prevention and Control Program, Rutgers Cancer Institute, New Brunswick, New Jersey.ORCID 0000-0001-9001-186X
Mi-Hyeon JangRutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.ORCID 0000-0001-6274-3588
Kitaw DemissieDepartment of Epidemiology and Biostatistics, SUNY Downstate Health Sciences University School of Public Health, Brooklyn, New York.ORCID 0000-0002-0554-714X
Chi-Chen HongDepartment of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0001-9212-2264
Elisa V BanderaCancer Prevention and Control Program, Rutgers Cancer Institute, New Brunswick, New Jersey.ORCID 0000-0002-8789-2755

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Tumor cell metabolism in actionR01CA163591 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI JOSHUA D RABINOWITZ, Eileen P. White · 2012 to 2026
$7.0M
Obesity, related comorbidities, and breast cancer outcomes in African AmericansR01CA185623 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI BANDERA, ELISA V, DEMISSIE, KITAW · 2014 to 2018
$6.2M
A Multilevel Approach to Cardiovascular Health in African American Breast Cancer Survivors: from Neighborhoods to MetabolomicsR00MD013300 · NIMHD · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI QIN, BO · 2020 to 2022
$735k
CLC NIH HHS 75N90021D00009National Cancer Institute (NCI) P30CA016056National Cancer Institute (NCI) P30CA072720National Cancer Institute (NCI) P30CA072720-6852National Cancer Institute (NCI) R01CA163591National Cancer Institute (NCI) R01CA185623National Institute on Minority Health and Health Disparities (NIMHD) R00MD013300NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA163591NCI NIH HHS R01 CA185623NHLBI NIH HHS 75N92021D00009NIEHS NIH HHS 75N96021D00009NIMHD NIH HHS R00 MD013300ORFDO NIH HHS 75N99021D00009
6 · The paper itself

Abstract

backgroundThe metabolomics approach using blood samples from epidemiologic studies has the potential to elucidate pathways or uncover biomarkers for breast cancer outcomes. Therefore, understanding the within-person reproducibility of the blood metabolome and the factors that influence metabolite levels over time in breast cancer survivors are crucial, but these remain largely unknown.

methodsWe estimated the within-person reproducibility of plasma metabolites in 61 Black breast cancer survivors from the Women's Circle of Health Follow-Up Study. Samples were collected from each participant at two time points, approximately 2 and 3 years after diagnosis. Untargeted metabolomic profiles were analyzed by Metabolon using ultrahigh-performance LC/MS-MS. We calculated the intraclass correlation coefficients (ICC) for each metabolite by dividing the between-person variance by the total variance. ICCs were compared across preanalytic factors (e.g., fasting) and participant characteristics using the Wilcoxon test.

resultsAmong 857 named metabolites, the median ICC was 0.58 (IQR: 0.44-0.70). Of the metabolites, 16.6% showed high within-person reproducibility (ICC ≥ 0.75), spanning all metabolite classes, whereas 65.6% had an ICC within 0.4 to 0.75, and 17.9% had an ICC < 0.4. Reasonable ICCs were also observed for nonfasting samples (median 0.53, IQR: 0.39-0.67), although lower than those for fasting samples (median 0.63, IQR: 0.45-0.77). ICCs were slightly lower in younger, nonobese participants and in women with estrogen receptor-positive breast cancer.

conclusionsThe within-person reproducibility of plasma metabolites over 1 year among breast cancer survivors was generally acceptable. IMPACT: A single-timepoint measurement could be useful in evaluating associations between metabolites and breast cancer outcomes.

Indexed as

Biomarkers, TumorBlack or African AmericanBreast NeoplasmsCancer SurvivorsMetabolomeAdultAgedCohort StudiesFemaleFollow-Up StudiesHumansMetabolomicsMiddle AgedReproducibility of ResultsBiomarkers, Tumor

Identifiers

PMID40178939
PMCPMC12130800

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.